Life Expectancy in 2040: What Do Clinical Experts Expect?

We use expert clinical and public health opinion to estimate likely changes in the prevention and treatment of important disease conditions and how they will affect future life expectancy. Focus groups were held including clinical and public health faculty with expertise in the six leading causes of death in the United States. Mortality rates and life tables for 2040 were derived by sex and age. Life expectancy at age 20 and 65 was compared to figures published by the Social Security Administration and to estimates from the Lee-Carter method. There was agreement among all three approaches that life expectancy at age 20 will increase by approximately one year per decade for females and males between now and 2040. According to the clinical experts, 70% of the improvement in life expectancy will occur in cardiovascular disease and cancer, while in the last 30 years most of the improvement has occurred in cardiovascular disease. Expert opinion suggests that most of the increase in life expectancy will be attributable to the already achieved reduction in smoking rates, especially for women.     

Human development and cross-border acquisitions

We examine the role of human development in US companies' decisions to engage in cross-border acquisitions. Utilizing the human development index (HDI) published by the United Nations Development Program (UNDP), we find that US firms make acquisitions in countries with strong HDI levels. Alternative factors such as institutional quality, life expectancy, telephone usage and school enrolments also have a positive influence on the cross-border acquisition decision. Further, we find a positive relationship between cross-border mergers and acquisitions (M&As) and HDI rankings relative to the United States. Our findings contribute to the literature that seeks to explain why so little capital flows from developed to developing economies.     

Firm life expectancy and the heterogeneity of the book-to-market effect

I argue that the reason the book-to-market effect is stronger in small stocks is because smaller stocks generally have shorter life expectancy and therefore shorter equity duration. I build a model in which the book-to-market effect is stronger in stocks with shorter life expectancy. Empirically, I use delisting probability as my proxy for life expectancy. The data support my model's central prediction and its additional implications for stock return and variance. My results provide a rational explanation for the heterogeneity of the book-to-market effect, evidence previously taken as support for behavioral explanations.     

Life expectancy--a commentary on this life table variable

In 1992, I wrote an article on a method of modifying the Decennial US Life Table to accommodate any pattern of excess mortality expressed in terms of excess death rate (EDR), for the specific purpose of calculating the reduced life expectancy, e. I believe this was the first article published in the Journal of Insurance Medicine (JIM) that dealt specifically with life expectancy as an index of survival and risk appraisal, never used in the classification of extra mortality risk in applicants for life insurance. In this commentary, I discuss the 1989-91 US Decennial Life Table in detail. I link the subject matter of the 1992 article with several more recent articles that also focus on the utility of life expectancy in underwriting structured settlement annuities and preparing reports on life expectancy for an attorney in a tort case. A few references are given for further reading on life table methodology and its use in the most accurate estimate of life expectancy, given the inherent limitations of the life table and the limited duration of follow-up studies.     

Gender Convergence in Human Survival and the Postponement of Death

It has been a long-accepted demographic maxim that females outlive males. Using data for England and Wales, we show that life expectancy at age 30 is converging, and continuation of this long-term trend suggests life expectancy could reach parity in 2030, resulting in considerable economic and social ramifications. The degree of parity in life expectancy is examined by comparing the historical record in four countries that show that convergence is not a new phenomenon. Contributory factors are considered including changes in male smoking habits and male employment patterns. A model is presented that considers gender differences in longevity using novel methods for analyzing life tables. It determines the ages from which death is being postponed, to the ages at which people now die, the relative speed at which these changes are taking place between genders, and how the changes observed are affecting survival prospects at different ages up to 2030. It finds that as life expectancy continues to rise there is accompanying convergence in modal age of death of between 92 and 93 years.     

U.S. Monetary Regimes and Optimal Monetary Policy in the Euro Area

Monetary policy in the United States has been documented to have switched from reacting weakly to inflation fluctuations during the 1970s, to fighting inflation aggressively from the early 1980s onward. In this paper, I analyze the impact of the U.S. monetary policy regime switches on the Eurozone. I construct a New Keynesian two‐country model where foreign (U.S.) monetary policy switches regimes over time. I estimate the model for the U.S. and the Euro Area using quarterly data and find that the United States has switched between those two regimes, in line with existing evidence. I show that foreign regime switches affect home (Eurozone) inflation and output volatility and their responses to shocks, substantially, as long as the home central bank commits to a time‐invariant interest rate rule reacting to domestic conditions only. Optimal policy in the home country instead requires that the home central bank reacts strongly to domestic producer‐price inflation and to international variables, such as imported goods relative prices. In fact, I show that currency misalignments and relative prices play a crucial role in the transmission of foreign monetary policy regime switches internationally. Interestingly, I show that only marginal gains arise for the Euro Area when the European Central Bank (ECB) adjusts its policy according to the monetary regime in the United States. Thus, a simple time‐invariant monetary policy rule with a strong reaction to Producer Price Index (PPI) inflation and relative prices is enough to counteract the effects of monetary policy switches in the United States.     

Government Bond Market Seasonality, Diversification, and Cointegration: International Evidence

Using government bond market data for the United States, Canada, the United Kingdom, Germany, France, and Japan, I investigate several hypotheses. Market efficiency is investigated by testing for seasonality and cointegration. The seasonality results are mixed. In regression tests, a January effect is detected in several markets (United States, Germany, France, United Kingdom, and Canada) using local currencies. However, in a nonparametric test, the January effect is supported only for France. When U.S. dollar returns are used, regression results also reveal a January effect for several markets (United States, Germany, France, and United Kingdom). These results are not confirmed by a nonparametric test. Correlation analysis shows considerable diversification opportunities for short‐term investors. Cointegration tests indicate that several of the markets share cointegrating vectors, increasing the possibilities of using other endogenous bond markets to better predict movements in a particular market.     

Minimum Death Rates and Maximum Life Expectancy: The Role of Concordant Ages

Only five populations have achieved maximum life expectancy (or best practice population) more than occasionally since 1900. The aim of this article is to understand how maximum life expectancy is achieved in the context of mortality transition. We explore this aim using the concepts of potential life expectancy, based on minimum rates at each age among all high longevity populations, and concordant ages. Concordant ages are defined as ages at which the minimum death rate occurs in the population with the maximum life expectancy. The results show the extent to which maximum life expectancy could increase through the realization of demonstrably achievable minimum rates. Concordant ages are concentrated at increasingly older ages over time, but they have produced more than half of the change in maximum life expectancy in almost all periods since 1900. This finding is attributed to their quantity and position whereby concordant ages are concentrated at the ages that have the greatest impact on mortality decline in a particular period. Based on mortality forecasts, we expect that concordant ages will continue to lead increases in female maximum life expectancy, but that they will play a weaker role in male maximum life expectancy.     

Die Gesundheitsausgaben in der letzten Lebensphase

The expenditures for healthcare in the last year of life fall with the age at death. According to this observation, the increase of the life expectancy should lead to a decrease of health expenditures. The available empirical data allows to verify this thesis. In the data, I find that the expenditures fall with the age at death at the same date. But, this does not lead to a decrease in healthcare expenditures as time goes by, because the declining effect of a growing live expectancy is much smaller than the increase of healthcare expenditures in every age at death.     

How to prepare a life expectancy report for an attorney in a tort case

The purpose of this methodology article is to describe a suitable format for a legally acceptable report on the life expectancy of the principal in a tort case that is being advocated or defended by an attorney. Life insurance medical directors and underwriters are clearly skilled and experienced in mortality risk classification for life insurance. However, the judicial system is accustomed to measuring excess mortality only in terms of reduced life expectancy. The analyst preparing the report must convert the excess mortality into a figure for reduced life expectancy and compare this with the life expectancy of persons matched by age, sex and race in the latest Decennial US Life Tables. This process is different from the life insurance underwriting process. A life table projected to age 109 must be constructed as an essential part of the report, and the entire process must be presented clearly and convincingly. There are good reasons why the excess death rate (EDR) should be used as the index of excess mortality in constructing the life table, in preference to the mortality ratio (MR), which is used most of the time in life insurance risk classification. All of these considerations are discussed in this article, which is based on a sample of 40 cases handled by the author, a retired life insurance medical director.     

Update on HIV infection

In the third decade of the global epidemic, it is evident that human immunodeficiency virus (HIV) disease is quite different from the disease first recognized among a small number of homosexual men in 1981. The spread of HIV has been particularly alarming in developing countries, especially sub-Saharan Africa and Southeast Asia, and it continues to threaten other populations in Eastern Europe, Latin America and the Caribbean. HIV therapeutic advances have resulted in a marked decrease in acquired immunodeficiency syndrome (AIDS) incidence and death in the United States and Western Europe. With the introduction of "triple therapy," antiretroviral treatment has resulted in an extraordinary increase in the quality of life and life expectancy among HIV-infected persons. However, the rate of decline in AIDS incidence and deaths from the latter part of 1998 through 2000 has slowed for a number of reasons. Even with the stabilization of HIV in Western countries, it remains as important as ever to follow sound insurance principles to address HIV risk. The clinical success stories have yet to be translated into the insurance realm. A very strict analysis of the medical literature will be needed.     

The economics of well-being

Gross domestic product has long been the chief measure of national success. But there's been a lot of talk lately about changing that, from economists and world leaders alike. GDP is under siege for three main reasons. First, it is flawed even on its own terms: It misses lots of economic activity (unpaid household work, for example) and, as a single-number representation of vast, complex systems, is inevitably skewed. Second, it fails to account for economic and environmental sustainability. And third, readily available alternative measures may reflect well-being far better, by taking into account factors such as educational achievement, health, and life expectancy. HBR's Justin Fox surveys historical and current views on how to assess national progress, from Jeremy Bentham to Robert Kennedy to Nicolas Sarkozy. He also looks at where we may be headed. The biggest success so far in the campaign to supplant or at least supplement GDP, he finds, is the UN's Human Development Index-on which the United States has never claimed the top spot.     

Mind the Gap: A Study of Cause-Specific Mortality by Socioeconomic Circumstances

Socioeconomic groups may be exposed to varying levels of mortality; this is certainly the case in the United Kingdom, where the gaps in life expectancy, differentiated by socioeconomic circumstances, are widening. The reasons for such diverging trends are yet unclear, but a study of cause-specific mortality may provide rich insight into this phenomenon. Therefore, we investigate the relationship between socioeconomic circumstances and cause-specific mortality using a unique dataset obtained from the U.K. Office for National Statistics. We apply a multinomial logistic framework; the reason is twofold. First, covariates such as socioeconomic circumstances are readily incorporated, and, second, the framework is able to handle the intrinsic dependence amongst the competing causes. As a consequence of the dataset and modeling framework, we are able to investigate the impact of improvements in cause-specific mortality by socioeconomic circumstances. We assess the impact using (residual) life expectancy, a measure of aggregate mortality. Of main interest are the gaps in life expectancy among socioeconomic groups, the trends in these gaps over time, and the ability to identify the causes most influential in reducing these gaps. This analysis is performed through the investigation of different scenarios: first, by eliminating one cause of death at a time; second, by meeting a target set by the World Health Organization (WHO), called WHO 25 × 25; and third, by developing an optimal strategy to increase life expectancy and reduce inequalities.     

Made in the U.S.A.? A Study of Firm Responses to Domestic Production Incentives

How do U.S. companies respond to incentives intended to encourage domestic manufacturing? I study the Domestic Production Activities Deduction (DPAD), which was enacted in the American Jobs Creation Act (AJCA) of 2004 and was the third largest U.S. corporate tax expenditure as of 2017. Using confidential data from the U.S. Bureau of Economic Analysis, I find greater average domestic investment spending of $95.5–$143.6 million, but only within the sample of domestic‐only firms and not until 2010, when the greatest statutory DPAD benefits were available. Additional evidence suggests that U.S. multinational claimants invest abroad rather than in the United States and that the increased investment by DPAD firms is accompanied by a reduction in the domestic workforce, consistent with a substitution of capital for labor. I also show that the delayed investment response is due to firms engaging in other responses first, such as changing corporate reporting to shift income across time and borders. Quantifying the extent of these effects contributes to the literature that studies this tax deduction and informs policy makers as to the effectiveness of both manufacturing incentives and U.S. corporate income tax rate reductions in stimulating real domestic activity.     

MARKET BEHAVIOR OF GRAINS EXPORTERS

This article develops and tests several models of market behaviorover the 1965–81 period to identify the market behaviorof each of the five largest grain exporters in rice, wheat,and coarse grains. The results show that the United States hasexerted price leadership in the rice and coarse grains markets.The remaining major exporters in these markets have behavedin a manner consistent with a small-country exporter model inwhich their market demand is perceived to be perfectly elasticat the world price set by the dominant exporter. The resultsfor wheat suggest a shared dominance between the United States,Canada, and Australia, with the European Community and Argentinabehaving as small-country exporters. The short-run export supply curves for the five largest exportersappear to be very unresponsive to price. For rice, only Japan'sexports were found to have a significant and positive responseto an increase in the world export price. For wheat and coarsegrains, only the United States' exports were estimated to bepositively and significantly related to the export price. An important implication of the current market behavior of themajor exporters is that the opportunity exists for all otherexporters to sell all they can at the world price. However,a significant risk exists that the United States will stop supportingthe world price through its loan rate mechanism. A provisionfor such a change, the crop marketing loan provision, was includedin the Food Security Act of 1985 for wheat and coarse grainsand has already been implemented for rice.      

“A Direct Approach to the Discounted Penalty Function”, Hansjörg Albrecher,Hans U. Gerber,and Hailiang Yang,Volume 14, No. 4, 2010

Abstract

Mortality improvements, especially of the elderly, have been a common phenomenon since the end of World War II. The longevity risk becomes a major concern in many countries because of underestimating the scale and speed of prolonged life. In this study we explore the increasing life expectancy by examining the basic properties of survival curves. Specifically, we check if there are signs of mortality compression (i.e., rectangularization of the survival curve) and evaluate what it means to designing annuity products. Based on the raw mortality rates, we propose an approach to verify if there is mortality compression. We then apply the proposed method to the mortality rates of Japan, Sweden, and the United States, using the Human Mortality Database. Unlike previous results using the graduated mortality rates, we found no obvious signs that mortality improvements are slowing down. This indicates that human longevity is likely to increase, and longevity risk should be seriously considered in pricing annuity products.     

Der Einfluss des demographischen Wandels auf die Ausgaben der Krankenversicherung

The analysis presented in this document investigates the question of whether the increase in life expectancy causes financial stress for health insurance systems or not. In particular, the authors focused on the financial impact of the ?costs of dying“ and how much these costs contribute to the total health costs. The article analyses an in-patient and an out-patient tariff of a large private health insurance company in Germany. It is based on health care costs of people who died in 1999 and of those who continued to live. The percentage of the costs of dying is often overestimated. However, the costs of those who continued to live increased overproportionately. In particular, this was true for the insured people over 80 years.The claim that the increase of life expectancy only postpones the high costs in the future and has no impact on the financial conditions of health insurance is doubtful. Older people live longer and have more opportunity to take medication and receive therapy for a longer period. Therefore we argue that longer life expectancy and other factors like progress in medical technology pose a severe threat on the financial stability of health insurance.     

预期寿命对中国养老保险支出的影响效应——基于省级面板数据的实证分析

利用1995—2014年我国31个省份的省级面板数据实证检验了预期寿命延长对我国养老金支出的影响效应。结果发现：人口平均预期寿命对我国养老金支出水平具有显著的正向影响。实证结果显示：研究样本期间内人口平均预期寿命的增加导致了我国养老金支出水平增加了0.94个百分点,对养老金支出水平增加的贡献度高达76%,成为了我国养老金支出增加的主导因素。随着我国人口预期寿命延长模式逐渐进入到以老年人口死亡率下降为主导,这种人口增龄效应对养老金支出的影响还会进一步增强和深入,在未来养老保险制度改革优化过程中需对预期寿命这一因素加以重点关注。     

Labor supply and government programs: A cross-country analysis

There are substantial cross-country differences in labor supply late in the life cycle (age 50+). A theory of labor supply and retirement decisions is developed to quantitatively assess the role of social security, disability insurance, and taxation for understanding differences in labor supply late in the life cycle across European countries and the United States. The findings support the view that government policies can go a long way towards accounting for the low labor supply late in the life cycle in the European countries relative to the United States, with social security rules accounting for the bulk of these effects.     

Discussion of ADRs,Analysts, and Accuracy: Does Cross‐Listing in the United States Improve a Firm's Information Environment and Increase Market Value?

Lang, Lins, and Miller [2002] investigate the relation between cross‐listing in the United States and information intermediation by analysts. The results suggest that cross‐listing in the United States increases analyst following and forecast accuracy and that both variables are associated with Tobin's Q. These findings are interesting and advance the cross‐listing literature in several ways. This discussion raises two issues. First, I highlight that the sources of cross‐listing effects are not obvious and are difficult to disentangle. To illustrate this point, I replicate the analysis using cross‐listed Canadian firms, for which mandated disclosures are held constant. Thus, if disclosure effects are important for documented cross‐listing effects, I expect to find no relation in the Canadian sample. The findings for forecast accuracy are consistent with this hypothesis. However, analyst following continues to be significantly higher for cross‐listed Canadian firms. These findings suggest that the sources of cross‐listing effects differ for analyst coverage and forecast accuracy. Second, I discuss the link between analyst variables, firm value, and cost of capital. As they are only tenuously related, I draw attention to some unresolved questions and areas for future research.